Erasca, Inc. announced two clinical trial collaboration and supply agreements (CTCSAs) with Novartis for the MEK inhibitor trametinib (MEKINIST®). The agreements will support the clinical development of the pan-RAF inhibitor naporafenib in combination with trametinib for the treatment of patients with RAS Q61X solid tumors in the Phase 1b SEACRAFT-1 trial and in patients with previously treated NRAS-mutant (NRASm) unresectable or metastatic melanoma in the randomized, pivotal Phase 3 SEACRAFT-2 trial. Erasca is sponsoring the trials, and Novartis is supplying trametinib at no cost.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.97 USD | +6.49% | +6.49% | -7.51% |
May. 17 | Erasca Acquires 2 Exclusive Worldwide Licenses for Preclinical RAS Programs | MT |
May. 17 | Erasca Prices $160 Million Common Stock Offering | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.51% | 320M | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- ERAS Stock
- News Erasca, Inc.
- Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials